CA2304482A1 - Methode de traitement de la mucoviscidose - Google Patents

Methode de traitement de la mucoviscidose Download PDF

Info

Publication number
CA2304482A1
CA2304482A1 CA002304482A CA2304482A CA2304482A1 CA 2304482 A1 CA2304482 A1 CA 2304482A1 CA 002304482 A CA002304482 A CA 002304482A CA 2304482 A CA2304482 A CA 2304482A CA 2304482 A1 CA2304482 A1 CA 2304482A1
Authority
CA
Canada
Prior art keywords
alkyl
group
hydrogen
phenyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002304482A
Other languages
English (en)
Inventor
William Louis Macias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2304482A1 publication Critical patent/CA2304482A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement de la mucoviscidose par administration à un humain en présentant la nécessité, d'une quantité efficace sur le plan thérapeutique d'un inhibiteur de sPLA¿2?, tel qu'un 1H-indole-3-glyoxylamide.
CA002304482A 1997-09-26 1998-09-23 Methode de traitement de la mucoviscidose Abandoned CA2304482A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6012897P 1997-09-26 1997-09-26
US60/060,128 1997-09-26
PCT/US1998/019906 WO1999016453A1 (fr) 1997-09-26 1998-09-23 Methode de traitement de la mucoviscidose

Publications (1)

Publication Number Publication Date
CA2304482A1 true CA2304482A1 (fr) 1999-04-08

Family

ID=22027540

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002304482A Abandoned CA2304482A1 (fr) 1997-09-26 1998-09-23 Methode de traitement de la mucoviscidose

Country Status (5)

Country Link
EP (1) EP1007056A1 (fr)
JP (1) JP2001517707A (fr)
AU (1) AU9664198A (fr)
CA (1) CA2304482A1 (fr)
WO (1) WO1999016453A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
IL129484A0 (en) * 1998-04-17 2000-02-29 Lilly Co Eli Substituted tricyclics
US6576654B1 (en) * 1998-09-23 2003-06-10 Eli Lilly And Company Method for the treatment of cystic fibrosis
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
WO2001055108A2 (fr) * 2000-01-25 2001-08-02 Eli Lilly And Company Methode de traitement d'inflammations au moyen d'inhibiteurs spla¿2?
JP2003527369A (ja) * 2000-03-13 2003-09-16 イーライ・リリー・アンド・カンパニー スルホンアミド誘導体
JPWO2002000621A1 (ja) 2000-06-29 2004-04-22 塩野義製薬株式会社 Ｘ型ｓＰＬＡ２阻害作用を有する化合物
JP2004505982A (ja) * 2000-08-04 2004-02-26 イーライ・リリー・アンド・カンパニー 新規なｓＰＬＡ２インヒビター
US6730694B1 (en) 2001-07-20 2004-05-04 Eli Lilly And Company sPLA2 inhibitors
WO2006099256A2 (fr) * 2005-03-11 2006-09-21 Vertex Pharmaceuticals Incorporated Modulateurs de transporteurs de cassette de liaison a l'atp
JP5552121B2 (ja) * 2008-09-04 2014-07-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のインドリジン阻害剤
JP2023529011A (ja) * 2020-06-12 2023-07-06 ヌクミト ファーマシューティカルズ シーオー．， エルティーディー． インデン化合物、その医薬組成物、及びそれらの治療応用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211783D0 (en) * 1992-06-04 1992-07-15 Ici Plc Amide derivatives
GB9214053D0 (en) * 1992-07-02 1992-08-12 Ici Plc Heterocyclic amides
US5436258A (en) * 1992-09-09 1995-07-25 Eli Lilly And Company Prevention of bone resorption
US5453443A (en) * 1994-07-20 1995-09-26 Merck Frosst Canada, Inc. Bis(aryloxy)alkanes as inhibitors of phospholipase A2 enzymes
GB9417956D0 (en) * 1994-09-02 1994-10-26 Merck Sharp & Dohme Therapeutic agents
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5618792A (en) * 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase

Also Published As

Publication number Publication date
JP2001517707A (ja) 2001-10-09
AU9664198A (en) 1999-04-23
EP1007056A1 (fr) 2000-06-14
WO1999016453A1 (fr) 1999-04-08

Similar Documents

Publication Publication Date Title
US6514984B1 (en) Treatment for alzheimer's disease
US6610728B2 (en) Method for treatment of non-rheumatoid arthritis
KR20180042356A (ko) 암 치료 방법
WO2001083456A1 (fr) Derives d'heteroaryle condenses
US20210300875A1 (en) Farnesoid x receptor agonists and uses thereof
WO2022037631A1 (fr) Dérivé hétérocyclique, son procédé de préparation et son utilisation
EP1007056A1 (fr) Methode de traitement de la mucoviscidose
CA2308269A1 (fr) Methode de traitement des troubles lies a l'apoptose au moyen de composes de glyoxylamide n-heterocycliques
CA2284757A1 (fr) Methode de traitement de la bronchite chronique
US6576654B1 (en) Method for the treatment of cystic fibrosis
US20030087944A1 (en) Method for the treatment of renal dysfunction with spla2 inhibitors
CA2310249A1 (fr) Traitement contre la maladie d'alzheimer
US6214855B1 (en) Method for the treatment of stroke using N-heterocyclic glyoxlyamide compounds
CA2358492A1 (fr) Polytherapie destinee au traitement de la septicemie
WO2001055108A2 (fr) Methode de traitement d'inflammations au moyen d'inhibiteurs spla¿2?
US20030092767A1 (en) Combination therapy for the treatment of inflammatory and respiratory diseases
WO2001049323A1 (fr) Therapie combinee destinee au traitement de maladies inflammatoires et respiratoires
WO2001066111A1 (fr) Compositions contenant des inhibiteurs potentiels de spla2 afin de traiter la douleur
US9066947B2 (en) Indolyl-substituted pyrazino[1,2-b]isoquinolines for cancer treatment
JP2003525901A (ja) ｓＰＬＡ２インヒビターによる腎臓機能障害の治療方法
US20030149000A1 (en) Method for the treatment of disorders associated with apoptosis using N-heterocyclic glyoxylamide compounds
JP2002504893A (ja) Ｎ−ヘテロ環グリオキサミド化合物を用いた脳卒中の治療方法

Legal Events

Date Code Title Description
FZDE Dead